{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:54:05Z","timestamp":1781733245460,"version":"3.54.5"},"reference-count":8,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Case Rep"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonist liraglutide is widely used in type 2 diabetes mellitus and obesity and is generally considered non-hepatotoxic, with only rare reports of idiosyncratic liver injury. We report the case of a 58-year-old obese woman with type 2 diabetes who developed marked hepatocellular injury 12 weeks after initiating liraglutide therapy, with alanine aminotransferase (ALT) 876 U\/L and aspartate aminotransferase (AST) 702 U\/L after exclusion of alternative causes. Liver enzyme levels improved rapidly following drug discontinuation. A supervised rechallenge resulted in recurrence of severe transaminitis (ALT 1245 U\/L, AST 980 U\/L) within 10 days, with RUCAM score of 11 supporting a highly probable drug-induced liver injury. This case highlights a rare but definite idiosyncratic hepatocellular injury associated with liraglutide. Prompt recognition, discontinuation, and avoidance of rechallenge are essential. Further pharmacovigilance is warranted to better characterize incidence and mechanisms and guide safe clinical use of GLP-1 therapies in practice settings.<\/jats:p>","DOI":"10.1177\/11795476261461221","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:45:23Z","timestamp":1781545523000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liraglutide-Induced Acute Hepatocellular Injury With Positive Rechallenge: A Case Report and Literature Review"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0386-6742","authenticated-orcid":false,"given":"Mohammad","family":"Adi","sequence":"first","affiliation":[{"name":"Damascus University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Tanta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohsanam","family":"Eshimova","sequence":"additional","affiliation":[{"name":"Samarkand State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saidbek","family":"Husanov","sequence":"additional","affiliation":[{"name":"Termez University of Economics and Service"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_3_7_2_2","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","year":"2012","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Glucagon-Like Peptide-1 (GLP-1) Analogues. [Updated 2019 Apr 10; cited 2026 Apr 23]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548500\/"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.674"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020106"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000547634"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6306149"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000868320.94587.6b"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303180615231011053011"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.18053\/jctres.09.202303.004"}],"container-title":["Clinical Medicine Insights: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795476261461221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795476261461221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795476261461221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:16:37Z","timestamp":1781730997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795476261461221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":8,"alternative-id":["10.1177\/11795476261461221"],"URL":"https:\/\/doi.org\/10.1177\/11795476261461221","relation":{},"ISSN":["1179-5476","1179-5476"],"issn-type":[{"value":"1179-5476","type":"print"},{"value":"1179-5476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"11795476261461221"}}